Keryx Biopharmaceuticals (NASDAQ:KERX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.


Player Avatar pchop123 (80.21) Submitted: 12/4/2012 10:19:45 AM : Outperform Start Price: $3.02 KERX Score: -8.95

More upside than downside with developments and stock already has momentum

Featured Broker Partners